These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35646521)

  • 1. Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade.
    Li Q; Chen C; Kong J; Li L; Li J; Huang Y
    Acta Pharm Sin B; 2022 May; 12(5):2533-2549. PubMed ID: 35646521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic Cell Death Inducing Fluorinated Mitochondria-Disrupting Helical Polypeptide Synergizes with PD-L1 Immune Checkpoint Blockade.
    Jeong SD; Jung BK; Ahn HM; Lee D; Ha J; Noh I; Yun CO; Kim YC
    Adv Sci (Weinh); 2021 Apr; 8(7):2001308. PubMed ID: 33854870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti-PD-L1 Therapy.
    Xiang Y; Chen L; Liu C; Yi X; Li L; Huang Y
    Small; 2022 Feb; 18(6):e2104591. PubMed ID: 34859582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy.
    Song S; Shim MK; Yang S; Lee J; Yun WS; Cho H; Moon Y; Min JY; Han EH; Yoon HY; Kim K
    Bioact Mater; 2023 Oct; 28():358-375. PubMed ID: 37334068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 6. In Situ Vaccination with Mitochondria-Targeting Immunogenic Death Inducer Elicits CD8
    Wang Y; Wang W; Gu R; Chen J; Chen Q; Lin T; Wu J; Hu Y; Yuan A
    Adv Sci (Weinh); 2023 Jul; 10(20):e2300286. PubMed ID: 37127892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
    Kofla G; Radecke C; Frentsch M; Walther W; Stintzing S; Riess H; Bullinger L; Na IK
    Oncoimmunology; 2022; 11(1):2068109. PubMed ID: 35496500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative Stress Amplifiers as Immunogenic Cell Death Nanoinducers Disrupting Mitochondrial Redox Homeostasis for Cancer Immunotherapy.
    Wan J; Zhang X; Li Z; Mo F; Tang D; Xiao H; Wang J; Rong G; Liu T
    Adv Healthc Mater; 2023 Apr; 12(9):e2202710. PubMed ID: 36527737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cascade-Targeted Enzyme-Instructed Peptide Self-Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death.
    Xie L; Ding Y; Zhang X; Zhang Z; Zeng S; Wang L; Yang Z; Liu Q; Hu ZW
    Small Methods; 2023 May; 7(5):e2201416. PubMed ID: 36965100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
    Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
    J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer.
    Sun D; Zou Y; Song L; Han S; Yang H; Chu D; Dai Y; Ma J; O'Driscoll CM; Yu Z; Guo J
    Acta Pharm Sin B; 2022 Jan; 12(1):378-393. PubMed ID: 35127393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bio-responsive Au-miR-183 inhibitor enhances immunotherapy in hepatocellular carcinoma by inducing immunogenic cell death.
    Yin L; Wei Y; Liu Y; Mo X; Song J; Cai W
    J Control Release; 2024 Apr; 368():498-517. PubMed ID: 38428529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining PD-L1 blockade with immunogenic cell death induced by AIE photosensitizer to improve antitumor immunity.
    Li J; Dai J; Zhuang Z; Meng Z; Hu JJ; Lou X; Xia F; Zhao Z; Tang BZ
    Biomaterials; 2022 Dec; 291():121899. PubMed ID: 36343606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cavitation assisted endoplasmic reticulum targeted sonodynamic droplets to enhanced anti-PD-L1 immunotherapy in pancreatic cancer.
    Chen J; Feng L; Jin P; Shen J; Lu J; Song Y; Wang G; Chen Q; Huang D; Zhang Y; Zhang C; Xu Y; Huang P
    J Nanobiotechnology; 2022 Jun; 20(1):283. PubMed ID: 35710424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactive oxygen species-responsive dual-targeted nanosystem promoted immunogenic cell death against breast cancer.
    Banstola A; Pandit M; Duwa R; Chang JH; Jeong JH; Yook S
    Bioeng Transl Med; 2023 Sep; 8(5):e10379. PubMed ID: 37693071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
    Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
    Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.
    Schaer DA; Geeganage S; Amaladas N; Lu ZH; Rasmussen ER; Sonyi A; Chin D; Capen A; Li Y; Meyer CM; Jones BD; Huang X; Luo S; Carpenito C; Roth KD; Nikolayev A; Tan B; Brahmachary M; Chodavarapu K; Dorsey FC; Manro JR; Doman TN; Donoho GP; Surguladze D; Hall GE; Kalos M; Novosiadly RD
    Clin Cancer Res; 2019 Dec; 25(23):7175-7188. PubMed ID: 31409612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy.
    Kumar A; Chamoto K; Chowdhury PS; Honjo T
    Elife; 2020 Mar; 9():. PubMed ID: 32122466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-immolative polymer-based immunogenic cell death inducer for regulation of redox homeostasis.
    Jeon J; Yoon B; Dey A; Song SH; Li Y; Joo H; Park JH
    Biomaterials; 2023 Apr; 295():122064. PubMed ID: 36827894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.